HK1221215A1 - -炔基咪唑衍生物和含有其作為有效成分的藥物 - Google Patents
-炔基咪唑衍生物和含有其作為有效成分的藥物Info
- Publication number
- HK1221215A1 HK1221215A1 HK16109196.5A HK16109196A HK1221215A1 HK 1221215 A1 HK1221215 A1 HK 1221215A1 HK 16109196 A HK16109196 A HK 16109196A HK 1221215 A1 HK1221215 A1 HK 1221215A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- zxc4
- medicine
- same
- active ingredient
- imidazole derivative
- Prior art date
Links
- 239000004480 active ingredient Substances 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013123968 | 2013-06-12 | ||
PCT/JP2014/065643 WO2014200075A1 (ja) | 2013-06-12 | 2014-06-12 | 4-アルキニルイミダゾール誘導体およびそれを有効成分として含有する医薬 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1221215A1 true HK1221215A1 (zh) | 2017-05-26 |
Family
ID=52022361
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16109196.5A HK1221215A1 (zh) | 2013-06-12 | 2016-08-02 | -炔基咪唑衍生物和含有其作為有效成分的藥物 |
Country Status (29)
Country | Link |
---|---|
US (2) | US9593081B2 (zh) |
EP (1) | EP3009426B1 (zh) |
JP (1) | JP6276760B2 (zh) |
KR (1) | KR102212981B1 (zh) |
CN (1) | CN105431416B (zh) |
AU (1) | AU2014279113B2 (zh) |
BR (1) | BR112015030315B1 (zh) |
CA (1) | CA2914997C (zh) |
DK (1) | DK3009426T3 (zh) |
ES (1) | ES2669977T3 (zh) |
HK (1) | HK1221215A1 (zh) |
HR (1) | HRP20180703T1 (zh) |
HU (1) | HUE039015T2 (zh) |
IL (1) | IL242912A0 (zh) |
LT (1) | LT3009426T (zh) |
MX (1) | MX369804B (zh) |
MY (1) | MY168609A (zh) |
NO (1) | NO3009426T3 (zh) |
NZ (1) | NZ715837A (zh) |
PH (1) | PH12015502745A1 (zh) |
PL (1) | PL3009426T3 (zh) |
PT (1) | PT3009426T (zh) |
RS (1) | RS57406B1 (zh) |
RU (1) | RU2662806C2 (zh) |
SG (1) | SG11201510121RA (zh) |
SI (1) | SI3009426T1 (zh) |
TR (1) | TR201807659T4 (zh) |
WO (1) | WO2014200075A1 (zh) |
ZA (1) | ZA201600135B (zh) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS57406B1 (sr) * | 2013-06-12 | 2018-09-28 | Kaken Pharmaceutical Co Ltd | Derivat 4-alkinil imidazola i lekovi koji ga sadrže kao aktivni sastojak |
CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
CN109983004A (zh) * | 2016-11-18 | 2019-07-05 | 美国陶氏益农公司 | 4-((6-(2-(2,4-二氟苯基)-1,1-二氟-2-羟基-3-(5-巯基-1h-1,2,4-三唑-1-基)丙基)吡啶-3-基)氧基)苄腈及制备方法 |
CA3063637A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | N-substituted indole derivatives |
ES2896476T3 (es) | 2017-05-18 | 2022-02-24 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina |
EA201992677A1 (ru) | 2017-05-18 | 2020-04-23 | Идорсия Фармасьютиклз Лтд | Пиримидиновые производные в качестве модуляторов pge2 рецепторов |
CA3063632A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Benzofurane and benzothiophene derivatives as pge2 receptor modulators |
LT3625222T (lt) | 2017-05-18 | 2021-11-10 | Idorsia Pharmaceuticals Ltd | Fenilo dariniai, kaip pge2 receptoriaus moduliatoriai |
JP7211358B2 (ja) | 2017-05-22 | 2023-01-24 | 小野薬品工業株式会社 | Ep4アンタゴニスト |
JP2020142989A (ja) * | 2017-06-21 | 2020-09-10 | Meiji Seikaファルマ株式会社 | イミダゾール誘導体及びそれを含有する医薬 |
CN117643587A (zh) * | 2018-02-05 | 2024-03-05 | 深圳市原力生命科学有限公司 | 用于治疗癌症的杂二环羧酸 |
CN108997252B (zh) * | 2018-07-27 | 2020-04-28 | 常州大学 | 一种恶二唑衍生物的绿色合成方法 |
EP4245301A1 (en) | 2020-11-13 | 2023-09-20 | ONO Pharmaceutical Co., Ltd. | Cancer treatment by combined use of ep4 antagonist and immune checkpoint inhibitor |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL365443A1 (en) | 2001-01-31 | 2005-01-10 | Pfizer Products Inc. | Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of pde4 isozymes |
PL368129A1 (en) * | 2001-08-09 | 2005-03-21 | Ono Pharmaceutical Co, Ltd. | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient |
JP2006506327A (ja) | 2002-05-23 | 2006-02-23 | セラテクノロジーズ インコーポレイティド | プロスタグランジンe2の受容体サブタイプep4のアンタゴニスト・ポリペプチド |
MXPA06002551A (es) | 2003-09-03 | 2006-06-20 | Pfizer | Compuestos de aril o heteroaril amida. |
DE602005015215D1 (de) | 2004-05-04 | 2009-08-13 | Raqualia Pharma Inc | Orthosubstituierte aryl- oder heteroarylamidverbindungen |
WO2005105732A1 (en) | 2004-05-04 | 2005-11-10 | Pfizer Japan Inc. | Substituted methyl aryl or heteroaryl amide compounds |
CA2597896A1 (en) * | 2005-02-16 | 2006-08-24 | Solvay Pharmaceuticals B.V. | 1h-imidazole derivatives as cannabinoid cb2 receptor modulators |
ES2392192T3 (es) | 2006-04-24 | 2012-12-05 | Merck Canada Inc. | Derivados de indol amida como antagonistas del receptor EP4 |
CA2654811A1 (en) | 2006-06-12 | 2007-12-21 | Merck Frosst Canada Ltd. | Indoline amide derivatives as ep4 receptor ligands |
AU2007283404B2 (en) | 2006-08-11 | 2013-04-18 | Merck Canada Inc. | Thiophenecarboxamide derivatives as EP4 receptor ligands |
JP5301469B2 (ja) * | 2007-02-26 | 2013-09-25 | メルク カナダ インコーポレイテッド | Ep4受容体アンタゴニストとしてのインドール及びインドリンシクロプロピルアミド誘導体 |
WO2009003861A1 (en) * | 2007-07-02 | 2009-01-08 | F. Hoffmann-La Roche Ag | Imidazole derivatives as ccr2 receptor antagonists |
US20110028463A1 (en) | 2007-07-03 | 2011-02-03 | Astellas Pharma Inc. | Amide compounds |
US8598355B2 (en) | 2008-05-14 | 2013-12-03 | Astellas Pharma Inc. | Amide compound |
CA2733247C (en) | 2008-08-14 | 2018-04-03 | Beta Pharma Canada Inc. | Heterocyclic amide derivatives as ep4 receptor antagonists |
WO2012039972A1 (en) | 2010-09-21 | 2012-03-29 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition |
EP2649061B1 (en) | 2010-12-10 | 2015-05-13 | Rottapharm Biotech S.r.l. | Pyridine amide derivatives as ep4 receptor antagonists |
WO2012103071A2 (en) * | 2011-01-25 | 2012-08-02 | Eisai R&D Management Co., Ltd. | Compounds and compositions |
EP2729445B1 (en) | 2011-07-04 | 2015-10-21 | Rottapharm Biotech S.r.l. | Cyclic amine derivatives as ep4 receptor antagonists |
RS57406B1 (sr) * | 2013-06-12 | 2018-09-28 | Kaken Pharmaceutical Co Ltd | Derivat 4-alkinil imidazola i lekovi koji ga sadrže kao aktivni sastojak |
-
2014
- 2014-06-12 RS RS20180743A patent/RS57406B1/sr unknown
- 2014-06-12 US US14/897,324 patent/US9593081B2/en active Active
- 2014-06-12 ES ES14811154.5T patent/ES2669977T3/es active Active
- 2014-06-12 PT PT148111545T patent/PT3009426T/pt unknown
- 2014-06-12 HU HUE14811154A patent/HUE039015T2/hu unknown
- 2014-06-12 AU AU2014279113A patent/AU2014279113B2/en active Active
- 2014-06-12 WO PCT/JP2014/065643 patent/WO2014200075A1/ja active Application Filing
- 2014-06-12 PL PL14811154T patent/PL3009426T3/pl unknown
- 2014-06-12 RU RU2015155585A patent/RU2662806C2/ru active
- 2014-06-12 SI SI201430707T patent/SI3009426T1/en unknown
- 2014-06-12 MY MYPI2015704535A patent/MY168609A/en unknown
- 2014-06-12 LT LTEP14811154.5T patent/LT3009426T/lt unknown
- 2014-06-12 BR BR112015030315-3A patent/BR112015030315B1/pt active IP Right Grant
- 2014-06-12 TR TR2018/07659T patent/TR201807659T4/tr unknown
- 2014-06-12 EP EP14811154.5A patent/EP3009426B1/en active Active
- 2014-06-12 NO NO14811154A patent/NO3009426T3/no unknown
- 2014-06-12 CN CN201480044505.6A patent/CN105431416B/zh active Active
- 2014-06-12 DK DK14811154.5T patent/DK3009426T3/en active
- 2014-06-12 KR KR1020167000476A patent/KR102212981B1/ko active IP Right Grant
- 2014-06-12 NZ NZ715837A patent/NZ715837A/en unknown
- 2014-06-12 SG SG11201510121RA patent/SG11201510121RA/en unknown
- 2014-06-12 MX MX2015017161A patent/MX369804B/es active IP Right Grant
- 2014-06-12 JP JP2015522867A patent/JP6276760B2/ja active Active
- 2014-06-12 CA CA2914997A patent/CA2914997C/en active Active
-
2015
- 2015-12-03 IL IL242912A patent/IL242912A0/en active IP Right Grant
- 2015-12-09 PH PH12015502745A patent/PH12015502745A1/en unknown
-
2016
- 2016-01-07 ZA ZA2016/00135A patent/ZA201600135B/en unknown
- 2016-08-02 HK HK16109196.5A patent/HK1221215A1/zh unknown
-
2017
- 2017-01-24 US US15/414,200 patent/US9855257B2/en active Active
-
2018
- 2018-05-07 HR HRP20180703TT patent/HRP20180703T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20180703T1 (hr) | Derivat 4-alkinil imidazola i lijek koji kao aktivni sastojak sadrži isti | |
HK1204773A1 (zh) | 吡唑衍生物及其醫藥用途 | |
IL238713A0 (en) | Self-regulating active pharmaceutical ingredient release | |
HK1223583A1 (zh) | 透皮釋放活性物質的系統 | |
ZA201603272B (en) | Pharmaceutical combination formulation comprising amlodipine, losartan and rosuvastatin | |
EP3050875A4 (en) | Novel imidazole derivative and therapeutical use thereof | |
EP3065547A4 (en) | Biscationic and triscationic amphiles as antimicrobial agents | |
EP2987786A4 (en) | AMIDOPYRIDINOL DERIVATIVE OR PHARMACEUTICAL, SALT AND PHARMACEUTICAL COMPOSITION THEREFOR AS ACTIVE SUBSTANCE | |
ZA201504520B (en) | Active ingredient microparticles | |
HK1205107A1 (zh) | 咪唑酮類衍生物、其藥物組合物和用途 | |
EP2974749A4 (en) | ACTIVE INGREDIENT GENERATING DEVICE | |
EP2968195A4 (en) | PHARMACEUTICAL FORMULATION WITH GLYCOSAMINOGLYCAN | |
IL243223B (en) | History of imidazole, their preparation and pharmaceutical preparations containing them | |
EP3080088A4 (en) | Alkylpyrazolyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof | |
EP2996612A4 (en) | Antiseptic delivery system | |
GB201316023D0 (en) | Continuous low dosing of an active ingredient | |
HK1223834A1 (zh) | 具有生物學活性的胰島素衍生物 | |
PL3043791T3 (pl) | Środek przeciwnowotworowy zawierający związek aminoacetonitrylowy jako substancję czynną | |
IL240447A0 (en) | Propionic-biaryl acid derivatives and their use as pharmaceutical preparations | |
IL244316A0 (en) | A new composition of a drug | |
IL240422B (en) | Bi-aryl derivatives of propionic acid and their use as medicinal preparations | |
EP2964257A4 (en) | TRANSCUTANEOUS DOSE FORMULATION | |
GB201316498D0 (en) | Topical Pharmaceutical formulation | |
AU2013901834A0 (en) | Formulations and Therapeutic Uses Thereof | |
GB201302851D0 (en) | Ingredient Wrap |